Further research is warranted to better understand the biological behavior of extramedullary plasmacytomas with t(11;14), as well as to evaluate the efficacy and safety of targeted therapies such as BCL-2 inhibitors in this context. The gene discussed is BCL2; the disease is plasmacytoma.